Tarsons Products earnings calls.

Tarsons Products reported consolidated Q3 FY26 revenue of ₹108 croreCurrent reported value: ₹108 crore. No comparable prior figure is available in the source record., up 12.8% YoYCurrent reported value: 12.8% YoY. No comparable prior figure is available in the source record., with EBITDA at ₹31.5Current reported value: 31.5. No comparable prior figure is available in the source record. crore (29.2Current reported value: 29.2. No comparable prior figure is available in the source record.% margin) and adjusted PAT of ₹6.4 crore, growing 21.4% YoYCurrent reported value: 21.4% YoY. No comparable prior figure is available in the source record.. The company is operating at near-full capacity in existing plants, with the new ₹600 crore capex at ParSCH getting partially commercialized—bioprocess containers are now selling in domestic and export markets, while cell culture products are slated for Q4 commissioning. Management projects full facility breakeven at ₹70-75 crCurrent ₹70-75 Cr. Reported change: Revenue threshold.ore revenue, with bioprocess alone capable of generating ₹150+ crCurrent ₹150+ Cr. Reported change: New capacity.ore at peak utilization. Pricing pressure persists from post-COVID capacity additions by competitors, and the GeM-driven government procurement environment remains challenging. The India-US and India-EU FTAs present meaningful export opportunities, with tariff reductions from 50% to 18% (US) and 6% to 0% (EU) potentially accelerating international growth. Risk factors include prolonged capacity glut keeping prices depressed, slower-than-anticipated customer qualification timelines for new products, and geopolitical uncertainty affecting global trade.